Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.0352W HIGH $5.76
Volume
3.36 M
Value Traded
20.74 M
Short % Float
1.85%
+9.5%Week
+14.11%1 Month
+4.18%3 Month
+19.74%6 Month
-95.23%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.13 M
EPS (TTM)
-2.96
P/E Ratio
-
Ent. Value
3.33 M
Total Shares
1.33 M
Float Shares
514.19 K
Insiders
28.78%
Institutions
1.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TTNP Catalyst Timeline
Dated clinical, regulatory and corporate events for Titan Pharmaceuticals, Inc.
Past FDA Catalysts and PDUFA Decisions
How TTNP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2018-01-22 | CAM2038 (injectable/depot buprenorphine; later approved as Brixadi), NDA | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F18 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
3
Drugs Scored
-
rNPV / MCap
Titan Pharmaceuticals, Inc. has significant pipeline risk (18/100), with 3 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every TTNP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Probuphine | opioid addiction | Phase 3 | 2015-06-09 | response rate probuphine: 96.4%; response rate sublingual: 87.6%; confidence interval: (0.009, 0.167)Read More | Titan Pharmaceuticals, Inc . TITAN PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM PHASE 3 STUDY OF PROBUPHINE FOR OPIOID ADDICTION New Drug Application Expected to Be Resubmitted in Second Half of 2015 Titan to Host ConfeRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lazar David E.Director, Officer (Chief Executive Officer), 10% Owner | Sell | -3,388,902 | $1.23 | 06/21/2023 |
Hedge Fund 13F Activity
Hedge Funds invested in TTNP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TTNP for Q2 2026. | ||||
TTNP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TTNP ranks across every disease it competes in
Competitive Position is a premium feature
See how TTNP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTTNP News
About Titan Pharmaceuticals, Inc.
Founded18-01-1996
BIOPHARMAWATCH ELITE PLUS
Trade the next TTNP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime